Skip to main content
Top
Published in: Obesity Surgery 9/2011

01-09-2011 | Review

The Growing Role of Bariatric Surgery in the Management of Type 2 Diabetes: Evidences and Open Questions

Authors: Luca Busetto, Paolo Sbraccia, Lucia Frittitta, Antonio E. Pontiroli

Published in: Obesity Surgery | Issue 9/2011

Login to get access

Abstract

The use of bariatric surgery in the clinical management of type 2 diabetes has been recently endorsed in the clinical practice recommendations released by the most influential diabetologic associations. However, authoritative critic voices about the application of metabolic surgery in type 2 diabetes continue to appear in diabetologic literature. In this review, we will try therefore to understand what the reasons for this apparent dichotomy. In this paper, we revised what we believe are now clear evidences about the role of bariatric surgery in the treatment of type 2 diabetes in patients with morbid obesity: the efficacy of bariatric surgery in metabolic control, the existence of plausible weight-independent metabolic mechanisms at least in some bariatric procedure, and the importance of the early referral to surgery in patients with firm indications. However, we stressed also the lack of clear high-quality long-term data about the effects of bariatric surgery in the prevention of both macro- and micro-vascular hard endpoints in patients with type 2 diabetes. The accrual of these results will be critical to completely clarify the risk/benefit ratio of bariatric surgery in diabetes, as compared to current pharmacologic therapies. This may be particularly important in patients in which data on long-term efficacy are still not completed, such as in patients with lower BMI levels.
Literature
1.
go back to reference Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult onset diabetes mellitus. Ann Surg. 1995;222:339–50.PubMedCrossRef Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult onset diabetes mellitus. Ann Surg. 1995;222:339–50.PubMedCrossRef
2.
go back to reference MacDonald KG, Long SD, Swanson MS, et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg. 1997;1:213–20.PubMedCrossRef MacDonald KG, Long SD, Swanson MS, et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg. 1997;1:213–20.PubMedCrossRef
3.
go back to reference Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–56.PubMedCrossRef Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–56.PubMedCrossRef
4.
go back to reference Sjöström L, Lindroos A-K, Peltonen M, et al. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N Eng J Med. 2004;351:2683–93.CrossRef Sjöström L, Lindroos A-K, Peltonen M, et al. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N Eng J Med. 2004;351:2683–93.CrossRef
5.
go back to reference Pontiroli AE, Folli F, Paganelli M, et al. Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity. A 4-year case-controlled study. Diabetes Care. 2005;28:2703–9.PubMedCrossRef Pontiroli AE, Folli F, Paganelli M, et al. Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity. A 4-year case-controlled study. Diabetes Care. 2005;28:2703–9.PubMedCrossRef
6.
go back to reference Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes. A randomized controlled trial. JAMA. 2008;299:316–23.PubMedCrossRef Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes. A randomized controlled trial. JAMA. 2008;299:316–23.PubMedCrossRef
7.
go back to reference Executive Summary: Standards of medical care in diabetes—2009. Diabetes Care 2009;32:S6-12. Executive Summary: Standards of medical care in diabetes—2009. Diabetes Care 2009;32:S6-12.
8.
go back to reference Chipkin SR, Goldberg RJ. Obesity surgery and diabetes: does a chance to cut mean a chance to cure? Am J Med. 2009;122:205–6.PubMedCrossRef Chipkin SR, Goldberg RJ. Obesity surgery and diabetes: does a chance to cut mean a chance to cure? Am J Med. 2009;122:205–6.PubMedCrossRef
9.
go back to reference Thaler JP, Cummings DE. Minireview: hormonal and metabolic mechanism of diabetes remission after gastrointestinal surgery. Endocrinol. 2009;150:2518–25.CrossRef Thaler JP, Cummings DE. Minireview: hormonal and metabolic mechanism of diabetes remission after gastrointestinal surgery. Endocrinol. 2009;150:2518–25.CrossRef
10.
go back to reference Shauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467–84. Shauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467–84.
11.
go back to reference Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulations and glucose metabolism. Ann Surg. 2004;240:236–42.PubMedCrossRef Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulations and glucose metabolism. Ann Surg. 2004;240:236–42.PubMedCrossRef
12.
go back to reference Laferrere B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet in glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:2479–85.PubMedCrossRef Laferrere B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet in glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:2479–85.PubMedCrossRef
13.
go back to reference Pattou F, Beraud G, Arnalsteen L, et al. Restoration of β-cell function after bariatric surgery in type 2 diabetics: a prospective controlled study comparing gastric banding and gastric bypass. Obes Surg. 2007;17:1041–3. Pattou F, Beraud G, Arnalsteen L, et al. Restoration of β-cell function after bariatric surgery in type 2 diabetics: a prospective controlled study comparing gastric banding and gastric bypass. Obes Surg. 2007;17:1041–3.
14.
go back to reference le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favour an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243:108–14.PubMedCrossRef le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favour an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243:108–14.PubMedCrossRef
15.
go back to reference Service GJ, Thompson GB, Service FJ, et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric bypass surgery. N Engl J Med. 2005;353:249–54.PubMedCrossRef Service GJ, Thompson GB, Service FJ, et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric bypass surgery. N Engl J Med. 2005;353:249–54.PubMedCrossRef
16.
go back to reference Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741–9.PubMedCrossRef Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741–9.PubMedCrossRef
17.
go back to reference Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623–30.PubMedCrossRef Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623–30.PubMedCrossRef
18.
go back to reference Furet JP, Kong LC, Tap J. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes. 2010;59:3049–57.PubMedCrossRef Furet JP, Kong LC, Tap J. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes. 2010;59:3049–57.PubMedCrossRef
19.
go back to reference Greco AV, Mingrone G, Giancaterini A, et al. Insulin resistance in morbid obesity. Reversal with intramyocellular fat depletion. Diabetes. 2002;51:144–51.PubMedCrossRef Greco AV, Mingrone G, Giancaterini A, et al. Insulin resistance in morbid obesity. Reversal with intramyocellular fat depletion. Diabetes. 2002;51:144–51.PubMedCrossRef
20.
go back to reference Dixon JB, Dixon AF, O'Brien P. Improvements in insulin sensitivity and beta-cell function (HOMA) with weight loss in the severely obese. Diabet Med. 2003;20:127–34.PubMedCrossRef Dixon JB, Dixon AF, O'Brien P. Improvements in insulin sensitivity and beta-cell function (HOMA) with weight loss in the severely obese. Diabet Med. 2003;20:127–34.PubMedCrossRef
21.
go back to reference Hall TC, Pellen MG, Sedman PC, et al. Preoperative factors predicting remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery for obesity. Obes Surg. 2010;20:1245–50.PubMedCrossRef Hall TC, Pellen MG, Sedman PC, et al. Preoperative factors predicting remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery for obesity. Obes Surg. 2010;20:1245–50.PubMedCrossRef
22.
go back to reference IDF. Bariatric surgical and procedural interventions in the treatment of obese patients with type 2 diabetes. A position statement from the International Diabetes Federation Taskforce on Epidemiology and Prevention; 2011. IDF. Bariatric surgical and procedural interventions in the treatment of obese patients with type 2 diabetes. A position statement from the International Diabetes Federation Taskforce on Epidemiology and Prevention; 2011.
23.
go back to reference Schernthaner G, Kopp H-P, Brix JM, et al. Cure of type 2 diabetes by metabolic surgery? A critical analysis of the evidence in 2010. Diabetes Care. 2011;34:S355–60.PubMedCrossRef Schernthaner G, Kopp H-P, Brix JM, et al. Cure of type 2 diabetes by metabolic surgery? A critical analysis of the evidence in 2010. Diabetes Care. 2011;34:S355–60.PubMedCrossRef
24.
25.
go back to reference Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32:2133–5.PubMedCrossRef Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32:2133–5.PubMedCrossRef
26.
go back to reference Stratton IM, Adler AI, Neil AW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.PubMedCrossRef Stratton IM, Adler AI, Neil AW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.PubMedCrossRef
27.
go back to reference UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef
28.
go back to reference Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.PubMedCrossRef Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.PubMedCrossRef
29.
go back to reference The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Eng J Med. 2008;358:2545–59.CrossRef The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Eng J Med. 2008;358:2545–59.CrossRef
30.
go back to reference The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Eng J Med. 2008;358:2560–72.CrossRef The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Eng J Med. 2008;358:2560–72.CrossRef
31.
go back to reference Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspectivepioglitAzone Clinical Trial In macroVascular Events): a randomized control trial. Lancet. 2005;366:1279–89.PubMedCrossRef Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspectivepioglitAzone Clinical Trial In macroVascular Events): a randomized control trial. Lancet. 2005;366:1279–89.PubMedCrossRef
32.
go back to reference Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Eng J Med. 2009;360:129–39.CrossRef Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Eng J Med. 2009;360:129–39.CrossRef
33.
go back to reference Mannucci E, Monami M, Lamanna C, et al. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2009;19:604–12.PubMedCrossRef Mannucci E, Monami M, Lamanna C, et al. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2009;19:604–12.PubMedCrossRef
34.
go back to reference Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Eng J Med. 2003;348:383–93.CrossRef Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Eng J Med. 2003;348:383–93.CrossRef
35.
go back to reference Gaede P, Lund-Andersen H, Parving HH, et al. Effect of multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.PubMedCrossRef Gaede P, Lund-Andersen H, Parving HH, et al. Effect of multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.PubMedCrossRef
36.
go back to reference Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375:481–9.PubMedCrossRef Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375:481–9.PubMedCrossRef
37.
go back to reference Fried M, Ribaric G, Buchwald JN, et al. Metabolic surgery for the treatment of type 2 diabetes in patients with BMI <35 kg/m2: an integrative review of early studies. Obes Surg. 2010;20:776–90.PubMedCrossRef Fried M, Ribaric G, Buchwald JN, et al. Metabolic surgery for the treatment of type 2 diabetes in patients with BMI <35 kg/m2: an integrative review of early studies. Obes Surg. 2010;20:776–90.PubMedCrossRef
38.
go back to reference Scopinaro N, Adami GF, Papadia FS, et al. The effects of biliopancreatic diversion on type 2 diabetes mellitus in patients with mild obesity (BMI 30–35 kg/m2) and simple overweight (BMI 25–30 kg/m2): a prospective controlled study. Obes Surg. 2011;21:880–8. Scopinaro N, Adami GF, Papadia FS, et al. The effects of biliopancreatic diversion on type 2 diabetes mellitus in patients with mild obesity (BMI 30–35 kg/m2) and simple overweight (BMI 25–30 kg/m2): a prospective controlled study. Obes Surg. 2011;21:880–8.
Metadata
Title
The Growing Role of Bariatric Surgery in the Management of Type 2 Diabetes: Evidences and Open Questions
Authors
Luca Busetto
Paolo Sbraccia
Lucia Frittitta
Antonio E. Pontiroli
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
Obesity Surgery / Issue 9/2011
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-011-0471-5

Other articles of this Issue 9/2011

Obesity Surgery 9/2011 Go to the issue